Draft — Novo Nordisk Fonden Open Competition Grants

MOTIVATION LETTER

The Conjunctive Consolidation Threshold model addresses a fundamental gap in addiction neuroscience: no existing pharmacotherapy prevents the encoding of reward-memory associations at the synaptic level. My independent research, conducted in Lagos without institutional affiliation, demonstrates that a triple-drug regimen targeting NMDA receptor, dopamine D1 receptor, and beta-adrenergic receptor simultaneously reduces reward-memory encoding probability from 0.855 to 0.122, an 85.8 percent reduction confirmed through ODE/RK45 numerical integration and Bayesian MCMC validation. The super-additivity effect of 12.8 percentage points above the sum of individual drug effects confirms the conjunctive mechanism predicted by the model.

The Novo Nordisk Foundation Open Competition Grants support health and life sciences research with translational potential. My CCT framework bridges computational neuroscience and clinical pharmacology, offering a testable intervention for substance use disorders that affect 35 million people globally according to WHO data. The mathematical specification, published on OSF (10.17605/OSF.IO/EMY4U), provides explicit differential equations governing the three-drug interaction dynamics. The Bayesian population dynamics preprint on Zenodo (10.5281/zenodo.20492472) includes a simulated clinical trial architecture with 200 virtual patients, showing 95 percent credible intervals that exclude the null for all five pre-registered hypotheses H1 through H5.

I hold a B.Pharm from the University of Ibadan with a German-equivalent grade of 1.9 and am a PCN-licensed pharmacist. My computational skills include Python with scipy, numpy, PyMC for Bayesian inference, and ODE/RK45 solvers; R for statistical analysis; and TDA libraries Ripser and Gudhi for topological data analysis. I built three open-source platforms: IMPRINT for addiction-liability screening, TOPOLOGIX for drug-protein interaction analysis using persistent homology, and GATE for BCI neural-stimulation safety evaluation, all released under Apache 2.0 licenses.

Endorsements from Kent Berridge at Michigan, Samuel Gershman at Harvard who provided my arXiv endorsement, Nathaniel Daw at Princeton, and Marcelo Mattar at NYU validate the theoretical foundation. A provisional patent on the CCT core architecture is filed for Q3 2026. A review article is under review at Neuroscience and Biobehavioral Reviews, and a co-authored paper is under review at Alcohol.

This grant would fund the next phase: in vitro validation using rodent hippocampal slice preparations to measure conjunctive threshold dynamics, followed by a pilot human pharmacokinetic study in Lagos. Nigeria has one of the highest rates of opioid and cannabis use disorders in West Africa, yet no dedicated computational pharmacology research programme exists. My work demonstrates that world-class computational neuroscience can originate from independent researchers in LMIC settings.

RESEARCH STATEMENT

The Conjunctive Consolidation Threshold model proposes that reward-memory encoding requires simultaneous activation of three distinct neural pathways: NMDA receptor-dependent glutamatergic signaling, dopamine D1 receptor activation, and beta-adrenergic receptor stimulation. The CCT posits that sub-threshold activation of any two pathways fails to trigger consolidation, but supra-threshold activation of all three produces stable memory encoding. This tripartite requirement creates a pharmacological window: partial blockade of all three pathways simultaneously prevents encoding without abolishing any single pathway entirely.

My formal mathematical specification defines the CCT as a sigmoidal function of three independent variables representing receptor occupancy fractions. The ODE system models the temporal dynamics of drug concentration, receptor binding, and downstream signaling cascades using standard pharmacokinetic parameters from published literature. Numerical integration using RK45 with adaptive step size yields the encoding probability under various drug combinations. Bayesian MCMC with 10,000 samples per condition provides posterior distributions for the interaction term, confirming super-additivity at 12.8 percentage points with a 95 percent HDI of 8.3 to 17.2 percentage points.

The clinical trial architecture in the Zenodo preprint specifies a three-arm, double-blind, placebo-controlled design with 200 participants randomized to placebo, single-drug, or triple-drug conditions. Primary endpoint is cue-induced craving at 24 hours post-administration, measured by the Obsessive Compulsive Drinking Scale adapted for polysubstance use. Power analysis indicates 80 percent power to detect a 30 percent reduction in craving scores at alpha 0.05. Secondary endpoints include drug-seeking behavior in a laboratory self-administration paradigm and fMRI BOLD response in nucleus accumbens and prefrontal cortex during cue exposure.

Nigeria presents unique advantages for this research. The population is genetically diverse, with high prevalence of CYP2D6 and CYP3A4 polymorphisms that affect drug metabolism. Pharmacokinetic variability across genetic subgroups will inform personalized dosing strategies. My clinical pharmacist experience at Ramset Pharmacy and current role as National Product Manager at Synthcare provide direct patient access and regulatory knowledge. The Lagos University Teaching Hospital has expressed interest in hosting a pilot study pending ethical approval.

The Novo Nordisk Foundation strategic areas include data science and clinical medicine. My computational approach combines both: Bayesian hierarchical models for population pharmacokinetics, topological data analysis for drug-protein interaction networks, and ODE-based mechanistic modeling for dose-response relationships. The TOPOLOGIX platform uses persistent homology on bipartite simplicial complexes to identify off-target interactions that could produce adverse effects, validated against hERG cardiotoxicity data with an MVP achieving 0.634 AUROC.

PROJECT DESCRIPTION

Objective: Validate the Conjunctive Consolidation Threshold model in vitro and design a Phase 1 clinical trial protocol for a triple-drug combination targeting reward-memory encoding in substance use disorder.

Specific Aim 1: Determine the conjunctive threshold parameters in rodent hippocampal slice preparations. I will measure long-term potentiation at Schaffer collateral-CA1 synapses under varying concentrations of MK-801 (NMDA antagonist), SCH-23390 (D1 antagonist), and propranolol (beta-blocker). The dependent variable is LTP magnitude at 60 minutes post-tetanus, normalized to baseline. I predict that triple-drug combinations at 30 percent receptor occupancy each will reduce LTP by at least 60 percent, while any single drug at 30 percent occupancy will produce less than 20 percent reduction. This experiment requires 48 slices from 12 rats, with 8 conditions including vehicle control, three single-drug conditions, three double-drug conditions, and one triple-drug condition. Statistical analysis uses ANOVA with Tukey post-hoc comparisons.

Specific Aim 2: Develop a population pharmacokinetic model for the triple-drug combination in healthy volunteers. I will recruit 30 participants in Lagos, stratified by CYP2D6 and CYP3A4 genotype. Each participant receives a single oral dose of the triple combination at the ratio predicted by the CCT model to produce 30 percent receptor occupancy for each drug. Blood samples collected at 0, 0.5, 1, 2, 4, 6, 8, 12, and 24 hours post-dose. Drug concentrations measured by LC-MS/MS at the University of Ibadan Central Laboratory. Nonlinear mixed-effects modeling in NONMEM will estimate population parameters and identify covariates affecting clearance and volume of distribution. The model will inform dose adjustments for the Phase 1 trial.

Specific Aim 3: Design a Phase 1 randomized, double-blind, placebo-controlled trial protocol. The protocol will specify inclusion criteria (DSM-5 alcohol use disorder, moderate to severe), exclusion criteria (current use of psychotropic medications, liver enzymes >3x upper limit of normal), dosing schedule (three doses per day for 7 days), and endpoints (cue-induced craving, drug-seeking behavior, adverse events). Sample size calculation: 60 participants randomized 2:1 to active drug or placebo. Primary analysis uses mixed-effects models for repeated measures. The protocol will be submitted to the Nigerian National Health Research Ethics Committee for approval.

Timeline: Months 1-3: rodent experiments at a collaborating laboratory in Ibadan. Months 4-6: pharmacokinetic study in Lagos. Months 7-9: protocol development and ethics submission. Months 10-12: data analysis and manuscript preparation.

Budget: Rodent experiments including animal purchase, housing, and reagents: 15,000 USD. LC-MS/MS assays for 30 participants with 9 time points each: 18,000 USD. Participant compensation and clinical staff: 12,000 USD. Equipment and software licenses: 5,000 USD. Travel and dissemination: 5,000 USD. Total: 55,000 USD.

BUDGET JUSTIFICATION

Rodent experiments: 12 adult male Sprague-Dawley rats at 50 USD each including shipping and quarantine. Housing at 5 USD per day for 30 days totals 1,800 USD. Reagents including MK-801, SCH-23390, propranolol, artificial cerebrospinal fluid, and recording electrodes: 3,200 USD. Slice preparation and electrophysiology equipment rental at the University of Ibadan Physiology Department: 5,000 USD. Technician support for 3 months at 500 USD per month: 1,500 USD. Total: 12,500 USD.

LC-MS/MS assays: 30 participants with 9 time points yields 270 samples. Assay cost per sample including internal standard, calibration curve, and quality controls: 50 USD. Consumables including tubes, needles, and storage: 2,000 USD. Shipping samples to the Central Laboratory: 1,000 USD. Total: 16,500 USD.

Participant compensation and clinical staff: 30 participants at 100 USD per participant for time and travel: 3,000 USD. Study physician for screening and monitoring at 2,000 USD per month for 3 months: 6,000 USD. Research nurse for blood draws and vital signs at 1,000 USD per month for 3 months: 3,000 USD. Total: 12,000 USD.

Equipment and software: NONMEM license for population PK modeling: 2,000 USD. Python and R software are open-source. High-performance computing time on the Nigerian Research and Education Network: 1,000 USD. Total: 3,000 USD.

Travel and dissemination: Conference travel to present results at the Society for Neuroscience annual meeting: 3,000 USD. Open-access publication fees: 2,000 USD. Total: 5,000 USD.

Indirect costs at 10 percent: 5,000 USD. Grand total: 55,000 USD.

PERSONAL STATEMENT

I began my research career as a clinical pharmacist at Ramset Pharmacy in Lagos, where I observed that patients with substance use disorders relapsed at rates exceeding 70 percent within six months of detoxification. The standard pharmacotherapy, naltrexone or acamprosate, showed modest efficacy at best. I asked a question that no existing literature answered: could we prevent the brain from encoding the memory of drug reward in the first place, rather than treating craving after the memory is established?

Without institutional support, I taught myself computational neuroscience using online resources from MIT OpenCourseWare and the Neuromatch Academy. I read every paper published by Kent Berridge on incentive salience, by Samuel Gershman on reinforcement learning, and by Nathaniel Daw on model-based versus model-free control. I corresponded with these researchers by email, sending them my mathematical derivations and asking for feedback. Berridge responded within a week, pointing out that my model needed to account for the role of orbitofrontal cortex in value representation. I incorporated his suggestion and the model improved.

The CCT framework emerged from a simple insight: if memory consolidation requires coincident detection of three signals, then partial blockade of all three should be more effective than complete blockade of any one. This is the opposite of the standard pharmacological approach, which aims for maximal receptor occupancy of a single target. My simulations confirmed the hypothesis, and I published three preprints on OSF and Zenodo with complete code and data for reproducibility.

I built IMPRINT, a web-based screening tool that calculates addiction liability for any compound using molecular descriptors and a random forest classifier trained on the Drug Abuse Potential database. TOPOLOGIX applies topological data analysis to drug-protein interaction networks, identifying off-target effects that could produce adverse reactions. GATE evaluates safety of brain-computer interface neural stimulation protocols. All three platforms are open-source and available on GitHub.

My Nigerian identity shapes my research priorities. Substance use disorders in Africa receive less than 1 percent of global research funding despite prevalence rates comparable to high-income countries. Pharmacogenetic diversity in African populations is systematically understudied, meaning that drugs developed in European populations may have different efficacy and toxicity profiles in African patients. My research directly addresses this gap by incorporating CYP2D6 and CYP3A4 genotyping into the clinical trial design.

I am applying for MSc programs at Medical University of Graz and University of Graz in Austria for October 2026 start. This grant would fund the research component of my transition from independent researcher to formal graduate student, providing the preliminary data needed for a competitive PhD application.

CHECKLIST

- [ ] Motivation letter (500 words maximum)
- [ ] Research statement (600 words maximum)
- [ ] Project description with specific aims, timeline, and budget (1000 words maximum)
- [ ] Budget justification (500 words maximum)
- [ ] Personal statement (500 words maximum)
- [ ] Curriculum vitae with ORCID, GitHub, and publication links
- [ ] Two letters of recommendation (one from a registered nurse collaborator, one from a computational neuroscience researcher)
- [ ] Proof of pharmacist licensure from Pharmacists Council of Nigeria
- [ ] Preprint links: OSF 10.17605/OSF.IO/KG7B5, OSF 10.17605/OSF.IO/EMY4U, Zenodo 10.5281/zenodo.20492472
- [ ] Provisional patent filing documentation for CCT core architecture
- [ ] Letter of collaboration from a registered nurse willing to serve as co-PI
- [ ] Institutional letter of support from University of Ibadan Physiology Department for rodent experiments
- [ ] Ethical approval documentation from Nigerian National Health Research Ethics Committee (or letter of intent to apply)

EDITOR NOTES

- Eligibility critical: The Novo Nordisk Foundation Open Competition Grants require the main applicant to be a registered nurse. Eniola is a pharmacist. The application must include a registered nurse as co-PI. Identify a specific nurse collaborator with addiction research experience and include their CV and letter of support. Without this, the application will be rejected on eligibility grounds.

- Budget verification: The total budget of 55,000 USD is within typical range for early-career grants but may exceed the Foundation's typical award size for open competition. Check the Foundation's published award amounts for similar proposals. If awards typically range 10,000-30,000 USD, scale the budget accordingly by reducing the rodent experiment scope or limiting the pharmacokinetic study to 15 participants.

- Institutional affiliation: Eniola is listed as an independent researcher. The Foundation may require institutional affiliation for grant administration. Confirm whether the University of Ibadan or a Lagos-based hospital can serve as the host institution for grant management. If not, consider partnering with a registered NGO or research institute in Nigeria.

- Publication status: The review article under review at Neuroscience and Biobehavioral Reviews and the co-authored paper at Alcohol are not yet accepted. Verify current status before submission. If rejected, replace with the accepted preprint citations and note that they are under review at specific journals.

- Patent timeline: The provisional patent is listed as Q3 2026, which is future tense. Confirm whether the patent has been filed or is still in preparation. If not yet filed, remove from the application or note as pending.

MOTIVATION LETTER

The Conjunctive Consolidation Threshold model addresses a fundamental gap in addiction neuroscience: no existing pharmacotherapy prevents the encoding of reward-memory associations at the synaptic level. My independent research, conducted in Lagos without institutional affiliation, demonstrates that a triple-drug regimen targeting NMDA receptor, dopamine D1 receptor, and beta-adrenergic receptor simultaneously reduces reward-memory encoding probability from 0.855 to 0.122, an 85.8 percent reduction confirmed through ODE/RK45 numerical integration and Bayesian MCMC validation. The super-additivity effect of 12.8 percentage points above the sum of individual drug effects confirms the conjunctive mechanism predicted by the model.

The Novo Nordisk Foundation Open Competition Grants support health and life sciences research with translational potential. My CCT framework bridges computational neuroscience and clinical pharmacology, offering a testable intervention for substance use disorders that affect 35 million people globally according to WHO data. The mathematical specification, published on OSF (10.17605/OSF.IO/EMY4U), provides explicit differential equations governing the three-drug interaction dynamics. The Bayesian population dynamics preprint on Zenodo (10.5281/zenodo.20492472) includes a simulated clinical trial architecture with 200 virtual patients, showing 95 percent credible intervals that exclude the null for all five pre-registered hypotheses H1 through H5.

I hold a B.Pharm from the University of Ibadan with a German-equivalent grade of 1.9 and am a PCN-licensed pharmacist. My computational skills include Python with scipy, numpy, PyMC for Bayesian inference, and ODE/RK45 solvers; R for statistical analysis; and TDA libraries Ripser and Gudhi for topological data analysis. I built three open-source platforms: IMPRINT for addiction-liability screening, TOPOLOGIX for drug-protein interaction analysis using persistent homology, and GATE for BCI neural-stimulation safety evaluation, all released under Apache 2.0 licenses.

Endorsements from Kent Berridge at Michigan, Samuel Gershman at Harvard who provided my arXiv endorsement, Nathaniel Daw at Princeton, and Marcelo Mattar at NYU validate the theoretical foundation. A provisional patent on the CCT core architecture is filed for Q3 2026. A review article is under review at Neuroscience and Biobehavioral Reviews, and a co-authored paper is under review at Alcohol.

This grant would fund the next phase: in vitro validation using rodent hippocampal slice preparations to measure conjunctive threshold dynamics, followed by a pilot human pharmacokinetic study in Lagos. Nigeria has one of the highest rates of opioid and cannabis use disorders in West Africa, yet no dedicated computational pharmacology research programme exists. My work demonstrates that world-class computational neuroscience can originate from independent researchers in LMIC settings.

RESEARCH STATEMENT

The Conjunctive Consolidation Threshold model proposes that reward-memory encoding requires simultaneous activation of three distinct neural pathways: NMDA receptor-dependent glutamatergic signaling, dopamine D1 receptor activation, and beta-adrenergic receptor stimulation. The CCT posits that sub-threshold activation of any two pathways fails to trigger consolidation, but supra-threshold activation of all three produces stable memory encoding. This tripartite requirement creates a pharmacological window: partial blockade of all three pathways simultaneously prevents encoding without abolishing any single pathway entirely.

My formal mathematical specification defines the CCT as a sigmoidal function of three independent variables representing receptor occupancy fractions. The ODE system models the temporal dynamics of drug concentration, receptor binding, and downstream signaling cascades using standard pharmacokinetic parameters from published literature. Numerical integration using RK45 with adaptive step size yields the encoding probability under various drug combinations. Bayesian MCMC with 10,000 samples per condition provides posterior distributions for the interaction term, confirming super-additivity at 12.8 percentage points with a 95 percent HDI of 8.3 to 17.2 percentage points.

The clinical trial architecture in the Zenodo preprint specifies a three-arm, double-blind, placebo-controlled design with 200 participants randomized to placebo, single-drug, or triple-drug conditions. Primary endpoint is cue-induced craving at 24 hours post-administration, measured by the Obsessive Compulsive Drinking Scale adapted for polysubstance use. Power analysis indicates 80 percent power to detect a 30 percent reduction in craving scores at alpha 0.05. Secondary endpoints include drug-seeking behavior in a laboratory self-administration paradigm and fMRI BOLD response in nucleus accumbens and prefrontal cortex during cue exposure.

Nigeria presents unique advantages for this research. The population is genetically diverse, with high prevalence of CYP2D6 and CYP3A4 polymorphisms that affect drug metabolism. Pharmacokinetic variability across genetic subgroups will inform personalized dosing strategies. My clinical pharmacist experience at Ramset Pharmacy and current role as National Product Manager at Synthcare provide direct patient access and regulatory knowledge. The Lagos University Teaching Hospital has expressed interest in hosting a pilot study pending ethical approval.

The Novo Nordisk Foundation strategic areas include data science and clinical medicine. My computational approach combines both: Bayesian hierarchical models for population pharmacokinetics, topological data analysis for drug-protein interaction networks, and ODE-based mechanistic modeling for dose-response relationships. The TOPOLOGIX platform uses persistent homology on bipartite simplicial complexes to identify off-target interactions that could produce adverse effects, validated against hERG cardiotoxicity data with an MVP achieving 0.634 AUROC.

PROJECT DESCRIPTION

Objective: Validate the Conjunctive Consolidation Threshold model in vitro and design a Phase 1 clinical trial protocol for a triple-drug combination targeting reward-memory encoding in substance use disorder.

Specific Aim 1: Determine the conjunctive threshold parameters in rodent hippocampal slice preparations. I will measure long-term potentiation at Schaffer collateral-CA1 synapses under varying concentrations of MK-801 (NMDA antagonist), SCH-23390 (D1 antagonist), and propranolol (beta-blocker). The dependent variable is LTP magnitude at 60 minutes post-tetanus, normalized to baseline. I predict that triple-drug combinations at 30 percent receptor occupancy each will reduce LTP by at least 60 percent, while any single drug at 30 percent occupancy will produce less than 20 percent reduction. This experiment requires 48 slices from 12 rats, with 8 conditions including vehicle control, three single-drug conditions, three double-drug conditions, and one triple-drug condition. Statistical analysis uses ANOVA with Tukey post-hoc comparisons.

Specific Aim 2: Develop a population pharmacokinetic model for the triple-drug combination in healthy volunteers. I will recruit 30 participants in Lagos, stratified by CYP2D6 and CYP3A4 genotype. Each participant receives a single oral dose of the triple combination at the ratio predicted by the CCT model to produce 30 percent receptor occupancy for each drug. Blood samples collected at 0, 0.5, 1, 2, 4, 6, 8, 12, and 24 hours post-dose. Drug concentrations measured by LC-MS/MS at the University of Ibadan Central Laboratory. Nonlinear mixed-effects modeling in NONMEM will estimate population parameters and identify covariates affecting clearance and volume of distribution. The model will inform dose adjustments for the Phase 1 trial.

Specific Aim 3: Design a Phase 1 randomized, double-blind, placebo-controlled trial protocol. The protocol will specify inclusion criteria (DSM-5 alcohol use disorder, moderate to severe), exclusion criteria (current use of psychotropic medications, liver enzymes >3x upper limit of normal), dosing schedule (three doses per day for 7 days), and endpoints (cue-induced craving, drug-seeking behavior, adverse events). Sample size calculation: 60 participants randomized 2:1 to active drug or placebo. Primary analysis uses mixed-effects models for repeated measures. The protocol will be submitted to the Nigerian National Health Research Ethics Committee for approval.

Timeline: Months 1-3: rodent experiments at a collaborating laboratory in Ibadan. Months 4-6: pharmacokinetic study in Lagos. Months 7-9: protocol development and ethics submission. Months 10-12: data analysis and manuscript preparation.

Budget: Rodent experiments including animal purchase, housing, and reagents: 15,000 USD. LC-MS/MS assays for 30 participants with 9 time points each: 18,000 USD. Participant compensation and clinical staff: 12,000 USD. Equipment and software licenses: 5,000 USD. Travel and dissemination: 5,000 USD. Total: 55,000 USD.

BUDGET JUSTIFICATION

Rodent experiments: 12 adult male Sprague-Dawley rats at 50 USD each including shipping and quarantine. Housing at 5 USD per day for 30 days totals 1,800 USD. Reagents including MK-801, SCH-23390, propranolol, artificial cerebrospinal fluid, and recording electrodes: 3,200 USD. Slice preparation and electrophysiology equipment rental at the University of Ibadan Physiology Department: 5,000 USD. Technician support for 3 months at 500 USD per month: 1,500 USD. Total: 12,500 USD.

LC-MS/MS assays: 30 participants with 9 time points yields 270 samples. Assay cost per sample including internal standard, calibration curve, and quality controls: 50 USD. Consumables including tubes, needles, and storage: 2,000 USD. Shipping samples to the Central Laboratory: 1,000 USD. Total: 16,500 USD.

Participant compensation and clinical staff: 30 participants at 100 USD per participant for time and travel: 3,000 USD. Study physician for screening and monitoring at 2,000 USD per month for 3 months: 6,000 USD. Research nurse for blood draws and vital signs at 1,000 USD per month for 3 months: 3,000 USD. Total: 12,000 USD.

Equipment and software: NONMEM license for population PK modeling: 2,000 USD. Python and R software are open-source. High-performance computing time on the Nigerian Research and Education Network: 1,000 USD. Total: 3,000 USD.

Travel and dissemination: Conference travel to present results at the Society for Neuroscience annual meeting: 3,000 USD. Open-access publication fees: 2,000 USD. Total: 5,000 USD.

Indirect costs at 10 percent: 5,000 USD. Grand total: 55,000 USD.

PERSONAL STATEMENT

I began my research career as a clinical pharmacist at Ramset Pharmacy in Lagos, where I observed that patients with substance use disorders relapsed at rates exceeding 70 percent within six months of detoxification. The standard pharmacotherapy, naltrexone or acamprosate, showed modest efficacy at best. I asked a question that no existing literature answered: could we prevent the brain from encoding the memory of drug reward in the first place, rather than treating craving after the memory is established?

Without institutional support, I taught myself computational neuroscience using online resources from MIT OpenCourseWare and the Neuromatch Academy. I read every paper published by Kent Berridge on incentive salience, by Samuel Gershman on reinforcement learning, and by Nathaniel Daw on model-based versus model-free control. I corresponded with these researchers by email, sending them my mathematical derivations and asking for feedback. Berridge responded within a week, pointing out that my model needed to account for the role of orbitofrontal cortex in value representation. I incorporated his suggestion and the model improved.

The CCT framework emerged from a simple insight: if memory consolidation requires coincident detection of three signals, then partial blockade of all three should be more effective than complete blockade of any one. This is the opposite of the standard pharmacological approach, which aims for maximal receptor occupancy of a single target. My simulations confirmed the hypothesis, and I published three preprints on OSF and Zenodo with complete code and data for reproducibility.

I built IMPRINT, a web-based screening tool that calculates addiction liability for any compound using molecular descriptors and a random forest classifier trained on the Drug Abuse Potential database. TOPOLOGIX applies topological data analysis to drug-protein interaction networks, identifying off-target effects that could produce adverse reactions. GATE evaluates safety of brain-computer interface neural stimulation protocols. All three platforms are open-source and available on GitHub.

My Nigerian identity shapes my research priorities. Substance use disorders in Africa receive less than 1 percent of global research funding despite prevalence rates comparable to high-income countries. Pharmacogenetic diversity in African populations is systematically understudied, meaning that drugs developed in European populations may have different efficacy and toxicity profiles in African patients. My research directly addresses this gap by incorporating CYP2D6 and CYP3A4 genotyping into the clinical trial design.

I am applying for MSc programs at Medical University of Graz and University of Graz in Austria for October 2026 start. This grant would fund the research component of my transition from independent researcher to formal graduate student, providing the preliminary data needed for a competitive PhD application.

CHECKLIST

- [ ] Motivation letter (500 words maximum)
- [ ] Research statement (600 words maximum)
- [ ] Project description with specific aims, timeline, and budget (1000 words maximum)
- [ ] Budget justification (500 words maximum)
- [ ] Personal statement (500 words maximum)
- [ ] Curriculum vitae with ORCID, GitHub, and publication links
- [ ] Two letters of recommendation (one from a registered nurse collaborator, one from a computational neuroscience researcher)
- [ ] Proof of pharmacist licensure from Pharmacists Council of Nigeria
- [ ] Preprint links: OSF 10.17605/OSF.IO/KG7B5, OSF 10.17605/OSF.IO/EMY4U, Zenodo 10.5281/zenodo.20492472
- [ ] Provisional patent filing documentation for CCT core architecture
- [ ] Letter of collaboration from a registered nurse willing to serve as co-PI
- [ ] Institutional letter of support from University of Ibadan Physiology Department for rodent experiments
- [ ] Ethical approval documentation from Nigerian National Health Research Ethics Committee (or letter of intent to apply)

EDITOR NOTES

- Eligibility critical: The Novo Nordisk Foundation Open Competition Grants require the main applicant to be a registered nurse. Eniola is a pharmacist. The application must include a registered nurse as co-PI. Identify a specific nurse collaborator with addiction research experience and include their CV and letter of support. Without this, the application will be rejected on eligibility grounds.

- Budget verification: The total budget of 55,000 USD is within typical range for early-career grants but may exceed the Foundation's typical award size for open competition. Check the Foundation's published award amounts for similar proposals. If awards typically range 10,000-30,000 USD, scale the budget accordingly by reducing the rodent experiment scope or limiting the pharmacokinetic study to 15 participants.

- Institutional affiliation: Eniola is listed as an independent researcher. The Foundation may require institutional affiliation for grant administration. Confirm whether the University of Ibadan or a Lagos-based hospital can serve as the host institution for grant management. If not, consider partnering with a registered NGO or research institute in Nigeria.

- Publication status: The review article under review at Neuroscience and Biobehavioral Reviews and the co-authored paper at Alcohol are not yet accepted. Verify current status before submission. If rejected, replace with the accepted preprint citations and note that they are under review at specific journals.

- Patent timeline: The provisional patent is listed as Q3 2026, which is future tense. Confirm whether the patent has been filed or is still in preparation. If not yet filed, remove from the application or note as pending.

AI Draft — Novo Nordisk Fonden Open Competition Grants